Last reviewed · How we verify
venlafaxine XR plus aripiprazole
venlafaxine XR plus aripiprazole is a SNRI plus atypical antipsychotic combination Small molecule drug developed by University of Pittsburgh. It is currently FDA-approved for Major depressive disorder, treatment-resistant, Major depressive disorder with psychotic features. Also known as: effexor XR, abilify.
Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms.
Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms. Used for Major depressive disorder, treatment-resistant, Major depressive disorder with psychotic features.
At a glance
| Generic name | venlafaxine XR plus aripiprazole |
|---|---|
| Also known as | effexor XR, abilify |
| Sponsor | University of Pittsburgh |
| Drug class | SNRI plus atypical antipsychotic combination |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Venlafaxine XR is an SNRI that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake transporters, treating depression and anxiety. Aripiprazole is an atypical antipsychotic that stabilizes dopamine signaling through partial agonism at D2 receptors, reducing psychotic symptoms and augmenting antidepressant efficacy. This combination is used in treatment-resistant depression and depression with psychotic features.
Approved indications
- Major depressive disorder, treatment-resistant
- Major depressive disorder with psychotic features
Common side effects
- Nausea
- Headache
- Insomnia
- Akathisia
- Weight gain
- Dizziness
Key clinical trials
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (PHASE4)
- Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- venlafaxine XR plus aripiprazole CI brief — competitive landscape report
- venlafaxine XR plus aripiprazole updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI
Frequently asked questions about venlafaxine XR plus aripiprazole
What is venlafaxine XR plus aripiprazole?
How does venlafaxine XR plus aripiprazole work?
What is venlafaxine XR plus aripiprazole used for?
Who makes venlafaxine XR plus aripiprazole?
Is venlafaxine XR plus aripiprazole also known as anything else?
What drug class is venlafaxine XR plus aripiprazole in?
What development phase is venlafaxine XR plus aripiprazole in?
What are the side effects of venlafaxine XR plus aripiprazole?
What does venlafaxine XR plus aripiprazole target?
Related
- Drug class: All SNRI plus atypical antipsychotic combination drugs
- Target: All drugs targeting Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor
- Manufacturer: University of Pittsburgh — full pipeline
- Therapeutic area: All drugs in Psychiatry / Mental Health
- Indication: Drugs for Major depressive disorder, treatment-resistant
- Indication: Drugs for Major depressive disorder with psychotic features
- Also known as: effexor XR, abilify
- Compare: venlafaxine XR plus aripiprazole vs similar drugs
- Pricing: venlafaxine XR plus aripiprazole cost, discount & access